$CTKB News

Cytek Biosciences (CTKB) Stock Sees Modest Fair Value Lift As Analysts Weigh Profitability

Cytek Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026

Fund Divests Cytek Biosciences (CTKB) Following Revenue Slowdown and Declining Profitability

Cytek® Biosciences Extends Capabilities Within Cytek Cloud Digital Ecosystem with New Cloud Analysis Tool

Is the Options Market Predicting a Spike in Cytek Biosciences Bank Stock?

Cytek Biosciences, Inc. (CTKB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry

Cytek’s (CTKB) Instruments Keep Selling While Losses Keep Growing

Cytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS

Jury Finds in Cytek’s Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding

Cytek Biosciences Says Jury Finds In Cytek’s Favor On Three Of Four Asserted Patent Claims; To Challenge Remaining Finding; Jury Awarded Past Damages Consisting Of $20M In Lost Profits And $36M In Royalties

Cytek (CTKB) Q2 2026 Earnings Call Transcript

Cytek Biosciences, Inc. Q2 2026 Earnings Call Summary

Cytek Biosciences, Inc. (CTKB) Q2 2026 Earnings Call Transcript

Cytek Biosciences, Inc. 2026 Q2 - Results - Earnings Call Presentation

Cytek Biosciences Inc (CTKB) (Q2 2026) Earnings Call Highlights: Revenue Up 6% to $48. ...

Cytek Biosciences Q2 Earnings Call Highlights

Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Tops Revenue Estimates

Cytek Biosciences Reports Second Quarter 2026 Financial Results

Cytek Biosciences Q2 EPS $(0.09), Inline, Sales $48.140M Miss $48.610M Estimate